The Influence of SARS-CoV-2 Variants B.1.1.7 and B.1.617.2 on a Different Clinical Course and Severity of COVID-19 in Children Hospitalized in 2021 Compared With 2020.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 Jul 2023
01 Jul 2023
Historique:
medline:
12
6
2023
pubmed:
14
4
2023
entrez:
13
4
2023
Statut:
ppublish
Résumé
This study aimed to analyze the differences in the epidemiologic and clinical characteristics of coronavirus disease 2019 (COVID-19) in children hospitalized in 2021, when the severe acute respiratory syndrome coronavirus 2 variants B.1.1.7 (alpha) and B.1.617.2 (delta) dominated, compared with 2020. In this multicenter study based on the pediatric part of the national SARSTer register (SARSTer-PED), we included 2771 children (0-18 years) with COVID-19 diagnosed between March 1, 2020, and December 31, 2021, from 14 Polish inpatient centers. An electronic questionnaire, which addressed epidemiologic and clinical data, was used. Children hospitalized in 2021 were younger compared with those reported in 2020 (mean 4.1 vs. 6.8 years, P = 0 .01). Underlying comorbidities were reported in 22% of the patients. The clinical course was usually mild (70%). A significant difference in the clinical course assessment between 2020 and 2021 was found, with more asymptomatic patients in 2020 and more severely ill children in 2021. In total, 5% of patients were severely or critically ill, including <3% of the participants in 2020 and 7% in 2021. The calculated mortality rate was 0.1% in general and 0.2% in 2021. Infections with severe acute respiratory syndrome coronavirus 2 variants alpha and delta lead to a more severe course of COVID-19 with more pronounced clinical presentation and higher fatality rates than infection with an original strain. Most of the children requiring hospitalization due to COVID-19 do not have underlying comorbidities.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to analyze the differences in the epidemiologic and clinical characteristics of coronavirus disease 2019 (COVID-19) in children hospitalized in 2021, when the severe acute respiratory syndrome coronavirus 2 variants B.1.1.7 (alpha) and B.1.617.2 (delta) dominated, compared with 2020.
METHODS
METHODS
In this multicenter study based on the pediatric part of the national SARSTer register (SARSTer-PED), we included 2771 children (0-18 years) with COVID-19 diagnosed between March 1, 2020, and December 31, 2021, from 14 Polish inpatient centers. An electronic questionnaire, which addressed epidemiologic and clinical data, was used.
RESULTS
RESULTS
Children hospitalized in 2021 were younger compared with those reported in 2020 (mean 4.1 vs. 6.8 years, P = 0 .01). Underlying comorbidities were reported in 22% of the patients. The clinical course was usually mild (70%). A significant difference in the clinical course assessment between 2020 and 2021 was found, with more asymptomatic patients in 2020 and more severely ill children in 2021. In total, 5% of patients were severely or critically ill, including <3% of the participants in 2020 and 7% in 2021. The calculated mortality rate was 0.1% in general and 0.2% in 2021.
CONCLUSION
CONCLUSIONS
Infections with severe acute respiratory syndrome coronavirus 2 variants alpha and delta lead to a more severe course of COVID-19 with more pronounced clinical presentation and higher fatality rates than infection with an original strain. Most of the children requiring hospitalization due to COVID-19 do not have underlying comorbidities.
Identifiants
pubmed: 37053572
doi: 10.1097/INF.0000000000003918
pii: 00006454-202307000-00011
pmc: PMC10289062
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
584-589Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Worldometers COVID-19 Data. Available at: https://www.worldometers.info/coronavirus/country/poland/ . Accessed November 5, 2022.
American Academy of Pediatrics. Children and COVID-19: State-Level Data Report. 2022. Available at: https://www.aap.org/ . Accessed November 5, 2022.
Lu X, Zhang L, Du H, et al.; Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 infection in children. N Engl J Med. 2020;382:1663–1665.
Team CC-R. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:422–426.
Parri N, Lenge M, Buonsenso D; Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) Research Group. Children with Covid-19 in pediatric emergency departments in Italy. N Engl J Med. 2020;383:187–190.
Pokorska-Spiewak M, Talarek E, Popielska J, et al. Comparison of clinical severity and epidemiological spectrum between coronavirus disease 2019 and influenza in children. Sci Rep. 2021;11:5760.
Zimmermann P, Curtis N. Why does the severity of COVID-19 differ with age?: understanding the mechanisms underlying the age gradient in outcome following SARS-CoV-2 Infection. Pediatr Infect Dis J. 2022;41:e36–e45.
Group ICC. COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. Infection. 2021;49:889–905.
Bundle N, Dave N, Pharris A, et al.; Study group members. COVID-19 trends and severity among symptomatic children aged 0-17 years in 10 European Union countries, 3 August 2020 to 3 October 2021. Euro Surveill. 2021;26:2101098.
Qi K, Zeng W, Ye M, et al. Clinical, laboratory, and imaging features of pediatric COVID-19: a systematic review and meta-analysis. Medicine (Baltim). 2021;100:e25230e25230.
UNICEF data: Monitoring the situation of children and women. Available at: https://data.unicef.org/covid-19-and-children/ . Accessed November 5, 2022.
Götzinger F, Strenger V. The role of children and young people in the transmission of SARS-CoV-2. Pediatr Infect Dis J. 2022;41:e172–e174.
Seriakova I, Yevtushenko V, Kramarov S, et al. Clinical course of COVID-19 in hospitalized children of Ukraine in different pandemic periods. Eur Clin Respir J. 2022;9:2139890.
Meyer M, Holfter A, Ruebsteck E, et al. The alpha variant (B.1.1.7) of SARS-CoV-2 in children: first experience from 3544 nucleic acid amplification tests in a cohort of children in Germany. Viruses. 2021;13:1600.
Sheng JF, Shao L, Wang YL. Clinical features of children with coronavirus disease 2019 caused by Delta variant infection. Zhongguo Dang Dai Er Ke Za Zhi. 2021;23:1267–1270.
Quintero AM, Eisner M, Sayegh R, et al. Differences in SARS-CoV-2 clinical manifestations and disease severity in children and adolescents by infecting variant. Emerg Infect Dis. 2022;28:2270–2280.
GISAID Database. Available at: https://nextstrain.org/groups/neherlab/ncov/poland . Accessed November 5, 2022.
European Centre for Disease Prevention and Control (ECDC). COVID-19 vaccine tracker. Stockholm: ECDC. Available at: https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#age-group-tab . Accessed November 5, 2022.
Boutzoukas AE, Zimmerman KO, Benjamin DK, et al. School safety, masking, and the delta variant. Pediatrics. 2021;149:e2021054396.
Mania A, Pokorska-Śpiewak M, Figlerowicz M, et al. Pneumonia, gastrointestinal symptoms, comorbidities, and coinfections as factors related to a lengthier hospital stay in children with COVID-19-analysis of a paediatric part of Polish register SARSTer. Infect Dis (Lond). 2022;54:196–204.
Mania A, Faltin K, Mazur-Melewska K, et al. Clinical picture and risk factors of severe respiratory symptoms in COVID-19 in children. Viruses. 2021;13:2366.
Pokorska-Śpiewak M, Talarek E, Mania A, et al. Clinical and epidemiological characteristics of 1283 pediatric patients with coronavirus disease 2019 during the first and second waves of the pandemic-results of the pediatric part of a multicenter polish register SARSTer. J Clin Med. 2021;10:5098.
European Medicines Agency. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/veklury . Accessed November 5, 2022.
Goldman DL, Aldrich ML, Hagmann SHF, et al. Compassionate Use of remdesivir in children with severe COVID-19. Pediatrics. 2021;147:e2020047803.